Scarica l'app Stockscreener
0.5425
3.48%
-0.0177
Precedente Chiudi:
$0.5602
Aprire:
$0.555
Volume 24 ore:
2.80M
Relative Volume:
16.88
Capitalizzazione di mercato:
$13.24M
Reddito:
-
Utile/perdita netta:
$-26.23M
Rapporto P/E:
-0.442
EPS:
-1.2274
Flusso di cassa netto:
$-10.29M
1 W Prestazione:
+28.77%
1M Prestazione:
-52.98%
6M Prestazione:
-74.25%
1 anno Prestazione:
-94.06%
Intervallo 1D:
$0.5245
$0.5799
Intervallo di 1 settimana:
$0.389
$0.6122
Portata 52W:
$0.3054
$13.85
Seastar Medical Holding Corp Stock (ICU) Company Profile
Nome
Seastar Medical Holding Corp
Settore
Industria
Telefono
844-427-8100
Indirizzo
3513 BRIGHTON BLVD, DENVER
Confronta ICU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICU
Seastar Medical Holding Corp
|
0.5407 | 13.24M | 0 | -26.23M | -10.29M | -1.2274 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Seastar Medical Holding Corp Borsa (ICU) Ultime notizie
ICU Secures U.S. DoD Grant for Advanced Burn and Injury Research - GuruFocus
Military Selects SeaStar Medical from 160 Companies for Critical Burn Treatment Research Grant - Stock Titan
How SeaStar Medical Is Leveraging Its Breakthrough Medical Device Designation To Help Critically Ill Patients - MSN
SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market - Yahoo Finance
SeaStar Medical secures second CMS trial coverage By Investing.com - Investing.com South Africa
SeaStar Medical (ICU) Secures CMS Coverage for Clinical Trial Ex - GuruFocus
SeaStar Medical secures second CMS trial coverage - Investing.com
SeaStar Medical Wins Elite CMS Coverage Status: Only 100 Trials Get This Medicare Advantage - Stock Titan
SeaStar Medical Advances Organ-Saving Therapies for Critically Ill Patients - citybuzz -
SeaStar Medical (ICU) Announces Offering of Common Stock Shares | ICU Stock News - GuruFocus
Prediction: Rocket Lab USA Is Going Global - The Globe and Mail
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
SeaStar Medical Holding Corporation (NASDAQ:ICU) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: SeaStar Medical sees revenue surge in Q1 2025 - Investing.com
SeaStar Medical Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView
SeaStar Medical Holding Corp SEC 10-Q Report - TradingView
SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
SeaStar Medical (ICU) Hits Key Milestone in Clinical Trial | ICU Stock News - GuruFocus
SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury - Yahoo Finance
SeaStar Medical to Report First Quarter Financial Results on May 14, 2025 - Stock Titan
Medical Device Co. SeaStar Seeks Toss Of Shareholder Suit - Law360
SeaStar Medical To Report First Quarter Financial Results On May 14, 2025 - Barchart.com
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately - Bluefield Daily Telegraph
Watch Live: SeaStar Medical CEO Reveals Latest Healthcare Innovation Insights on Benzinga - Stock Titan
SeaStar Medical Announces CEO Interview on Benzinga All - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
SeaStar Medical files to sell 3.5M shares of common stock for holders - MSN
ICU STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Seastar Medical Holding Corp. Investors with Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
ICU stock hits 52-week low at $1.2 amid market challenges - Investing.com
SeaStar Medical gains two new FDA breakthrough designations By Investing.com - Investing.com Australia
SeaStar Medical gains two new FDA breakthrough designations - Investing.com
Major FDA Win: SeaStar's Revolutionary Therapy Targets 45,000 Cardiac Surgery Patients - Stock Titan
Analyzing SeaStar Medical (NASDAQ:ICU) and Solventum (NYSE:SOLV) - Defense World
ICU stock hits 52-week low at $1.5 amid market challenges - Investing.com
SeaStar Medical reports USD 24.8 million loss in FY 2024 - Medical Buyer
Earnings call transcript: SeaStar Medical sees stock dip after Q4 2024 - Investing.com India
SeaStar Medical Holding Corp reports results for the quarter ended December 31Earnings Summary - TradingView
SeaStar Medical Achieves Key Milestones: FDA-Approved Therapy Generates Initial Sales - Stock Titan
SeaStar Medical Holding Corp expected to post a loss of 89 cents a shareEarnings Preview - TradingView
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - The Manila Times
Healthcare Innovator SeaStar Medical Announces Key Financial Results Date: Critical Care Progress in Focus - Stock Titan
NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award - Quantisnow
Groundbreaking Pediatric Kidney Treatment Earns SeaStar Medical Prestigious NKF Award - Stock Titan
ICU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Seastar Medical Holding Corp. to Contact the Firm Today! - ACCESS Newswire
Denver medical tech company fights to maintain Nasdaq listing - The Business Journals
SeaStar Medical secures Nasdaq listing extension By Investing.com - Investing.com Australia
SeaStar Medical secures Nasdaq listing extension - Investing.com India
SeaStar Medical’s director John Neuman acquires $153,227 in shares By Investing.com - Investing.com Canada
Seastar Medical Holding Corp Azioni (ICU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Seastar Medical Holding Corp Azioni (ICU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baird Jennifer A | Director |
Jun 30 '25 |
Buy |
0.42 |
10,000 |
4,174 |
28,000 |
| Neuman John | Director |
Jun 24 '25 |
Buy |
0.36 |
40,000 |
14,396 |
80,000 |
| Baird Jennifer A | Director |
May 20 '25 |
Buy |
1.28 |
10,000 |
12,815 |
10,000 |
| Chung Kevin | Chief Medical Officer |
May 20 '25 |
Buy |
1.25 |
4,500 |
5,625 |
18,185 |
| Neuman John | Director |
Aug 15 '24 |
Buy |
5.24 |
10,000 |
52,396 |
30,000 |
| Neuman John | Director |
Dec 11 '24 |
Buy |
2.04 |
10,000 |
20,405 |
40,000 |
| Chung Kevin | Chief Medical Officer |
Nov 18 '24 |
Buy |
1.99 |
4,250 |
8,458 |
13,685 |
| Chung Kevin | Chief Medical Officer |
Sep 30 '24 |
Buy |
4.26 |
1,000 |
4,258 |
9,435 |
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):